作者: Liang Shan , Paul C. Wang
DOI:
关键词: Clinical Practice 、 Preclinical stage 、 Imaging agent 、 Magnetic resonance imaging 、 Autologous cell 、 Neuroscience 、 Cell tracking 、 Medicine 、 Homing (hematopoietic) 、 Cellular imaging 、 Bioinformatics
摘要: Personalized diagnosis and treatment with allogenic or autologous cells have been intensively investigated over the past decade. Despite promising findings in preclinical studies, clinical results to date largely disappointing. Some critical issues remain be solved, such as how monitor migration, homing, survival, function of transplanted vivo. In years, imaging techniques introduced solve these based on a concept that can transformed cellular agent following labeling an agent. For this purpose, magnetic resonance (MRI) is so far first choice modality iron oxide-based nanoparticles are most frequently applied agents. However, MRI cell tracking studies currently still limited vivo visualization labeled cells, some elements for often incompletely characterized, which makes it difficult validate metaanalyze data generated from different studies. Incomplete information also slows transition practice. A robust protocol apparently deal issues. review, we briefly discuss limitations oxide then recommend minimum set essential should considered at stage.